Angiotensin-(1-7)
Recurrent Uterine Sarcoma
Wake Forest University Health SciencesPhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Uterine Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Case Comprehensive Cancer Center | Phase 3 | BB |
Ziv-Aflibercept National Cancer Institute (NCI) | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
Temsirolimus National Cancer Institute (NCI) | Phase 1 | CCC |
Gdc-0449 National Cancer Institute (NCI) | Phase 1/2 | CCC |
View all 14 →
Same molecule, other indications
Angiotensin-(1-7) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →